Oral semaglutide improved liver health, diabetes status, and lipid profile in patients with MASLD and T2D, with weight loss ...

Oral semaglutide is currently approved under the brand name Rybelsus ® as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Based on these findings, ...

On October 21, Novo Nordisk announced positive news on the cardiovascular benefits of its oral GLP-1R agonist, Rybelsus, ...

An oral formulation of semaglutide, taken daily, is more effective at reducing the risk of major adverse cardiovascular ...

Novo Nordisk NVO announced positive top-line data from a late-stage cardiovascular outcomes study that evaluated its oral ...

In Novo Nordisk’s randomized clinical trial, semaglutide reduced the risk for major adverse cardiovascular events by 14% ...

According to new data from the SOUL trial Oral semaglutide reduced MACE by 14% in Type 2 Diabetes patients. Novo Nordisk will ...

Novo Nordisk today announced the headline results from the SOUL cardiovascular outcomes trial. The double-blinded, randomized ...

As Novo Nordisk’s injectable diabetes-obesity duo Ozempic and Wegovy grab all the limelight, an oral version of the ...

Novo Nordisk's SOUL trial reveals a 14% reduction in major cardiovascular events with oral semaglutide in patients with type ...

Novo Nordisk A/S (NVO) announced Monday the headline results from the SOUL cardiovascular outcomes trial, which achieved its primary ...

A new meta-analysis confirms that semaglutide drugs like Ozempic are not only effective for weight loss, but can also protect ...